On February 02, 2016 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, reported that it will host a live teleconference and webcast at 10:00 a.m. Eastern Time (3:00 p.m. GMT) today (Tuesday February 2, 2016) to discuss the expansion of their strategic collaboration with GSK and the acceleration of the NY-ESO program (Press release, Adaptimmune, FEB 2, 2016, View Source;p=RssLanding&cat=news&id=2134756 [SID:1234509344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast of the conference call will be made available via Adaptimmune’s corporate website at www.adaptimmune.com on the events page. An archive will be available after the call at the same address.

To participate in the live conference call, if preferred, please dial (877) 280-2296 (U.S.) or +44 (0)20 7136 2056 or 0800 279 4992 (United Kingdom). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (5656147).